Safety evaluation of allogeneic umbilical cord blood mononuclear cell therapy for degenerative conditions.
8/1/2010 J Transl Med. 2010 Aug 3;8:75 Yang WZ, Zhang Y, Wu F, Min WP, Minev B, Zhang M, Luo XL, Ramos F, Ichim TE, Riordan NH, Hu X. Background: The current paradigm for cord blood transplantation is that HLA matching and immune suppression are strictly required to prevent graft versus host disease (GVHD). Immunological…
Stem cell therapy for autism.
6/1/2007 J Transl Med. 2007 Jun 27;5:30 Ichim TE, Solano F, Glenn E, Morales F, Smith L, Zabrecky G, Riordan NH. Autism spectrum disorders (ASD) are a group of neurodevelopmental conditions whose incidence is reaching epidemic proportions, afflicting approximately 1 in 166 children. Autistic disorder, or autism is the most common form of ASD. Although…
Cord blood in regenerative medicine: do we need immune suppression?
1/1/2007 J Transl Med. 2007 Jan 30;5:8 Riordan NH, Chan K, Marleau AM, Ichim TE. Cord blood is currently used as an alternative to bone marrow as a source of stem cells for hematopoietic reconstitution after ablation. It is also under intense preclinical investigation for a variety of indications ranging from stroke, to limb ischemia,…